RBC Capital Markets analysts scrutinized US biotech takeover speculation across major financial outlets from 2021 onward. Their findings underscore the volatility of early-stage M&A rumors, particularly highlighting Betaville - a single-source rumor mill founded by Ben Harrington - as a problematic information conduit. RBC's report cautions that reporting rumors prematurely carries significant risk, contrasting sharply with the safer approach of waiting for official announcements.

The analysis specifically flags CG Oncology, Legend Biotech, Xenon Pharmaceuticals, and Dyne Therapeutics as vulnerable targets, while noting speculation around Revolution Medicines may have inflated its valuation beyond reasonable acquisition multiples. RBC's rumourtrage analysis also identifies Rhythm Pharmaceuticals as a frequent investor favorite for takeovers, alongside Wave Life Sciences, Arrowhead Pharmaceuticals, and Neumora Therapeutics as compelling opportunities. BioCryst Pharmaceuticals and Ocular Therapeutix complete the list of companies under speculative scrutiny. The study concludes that while the game of chasing takeover rumors remains flawed, the analytical tools to navigate it have improved.